These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 38297066)

  • 1. Lipoprotein(a) is associated with DNA damage in patients with heterozygous familial hypercholesterolemia.
    Woźniak E; Broncel M; Woźniak A; Satała J; Pawlos A; Bukowska B; Gorzelak-Pabiś P
    Sci Rep; 2024 Jan; 14(1):2564. PubMed ID: 38297066
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association between lipoprotein (a) and proprotein convertase substilisin/kexin type 9 in patients with heterozygous familial hypercholesterolemia: A case-control study.
    Sun D; Li S; Zhao X; Wu NQ; Zhu CG; Guo YL; Gao Y; Qing P; Cui CJ; Liu G; Sun J; Dong Q; Li JJ
    Metabolism; 2018 Feb; 79():33-41. PubMed ID: 29129821
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Familial hypercholesterolemia and elevated lipoprotein(a): double heritable risk and new therapeutic opportunities.
    Vuorio A; Watts GF; Schneider WJ; Tsimikas S; Kovanen PT
    J Intern Med; 2020 Jan; 287(1):2-18. PubMed ID: 31858669
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and Safety of Alirocumab in High-Risk Patients With Clinical Atherosclerotic Cardiovascular Disease and/or Heterozygous Familial Hypercholesterolemia (from 5 Placebo-Controlled ODYSSEY Trials).
    McCullough PA; Ballantyne CM; Sanganalmath SK; Langslet G; Baum SJ; Shah PK; Koren A; Mandel J; Davidson MH
    Am J Cardiol; 2018 Apr; 121(8):940-948. PubMed ID: 29472008
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of Polyvascular Disease in Heterozygous Familial Hypercholesterolemia: Its Association With Circulating Lipoprotein(a) Levels.
    Funabashi S; Kataoka Y; Hori M; Ogura M; Doi T; Noguchi T; Harada-Shiba M
    J Am Heart Assoc; 2022 Aug; 11(16):e025232. PubMed ID: 35929461
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lipoprotein(a) in hereditary hypercholesterolemia: Influence of the genetic cause, defective gene and type of mutation.
    Marco-Benedí V; Cenarro A; Laclaustra M; Larrea-Sebal A; Jarauta E; Lamiquiz-Moneo I; Calmarza P; Bea AM; Plana N; Pintó X; Martín C; Civeira F
    Atherosclerosis; 2022 May; 349():211-218. PubMed ID: 34456049
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association between lipoprotein(a) concentrations and atherosclerotic cardiovascular disease risk in patients with familial hypercholesterolemia: an analysis from the HELLAS-FH.
    Anagnostis P; Rizos CV; Skoumas I; Rallidis L; Tziomalos K; Skalidis E; Kotsis V; Doumas M; Kolovou G; Sfikas G; Garoufi A; Lambadiari V; Dima I; Kiouri E; Agapakis D; Zacharis E; Antza C; Kolovou V; Koumaras C; Bantouvakis G; Liamis G; Liberopoulos EN
    Endocrine; 2022 May; 76(2):324-330. PubMed ID: 35262845
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In pediatric familial hypercholesterolemia, lipoprotein(a) is more predictive than LDL-C for early onset of cardiovascular disease in family members.
    Zawacki AW; Dodge A; Woo KM; Ralphe JC; Peterson AL
    J Clin Lipidol; 2018; 12(6):1445-1451. PubMed ID: 30150142
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lipoprotein(a) levels in children with homozygous familial hypercholesterolaemia: A cross-sectional study.
    de Boer LM; Reijman MD; Hutten BA; Wiegman A
    J Clin Lipidol; 2023; 17(3):415-419. PubMed ID: 37087364
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Equivalent Impact of Elevated Lipoprotein(a) and Familial Hypercholesterolemia in Patients With Atherosclerotic Cardiovascular Disease.
    Hedegaard BS; Bork CS; Kaltoft M; Klausen IC; Schmidt EB; Kamstrup PR; Langsted A; Nordestgaard BG
    J Am Coll Cardiol; 2022 Nov; 80(21):1998-2010. PubMed ID: 36396201
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Depicting new pharmacological strategies for familial hypercholesterolaemia involving lipoprotein (a).
    Vuorio A; Watts GF; Kovanen PT
    Eur Heart J; 2017 Dec; 38(48):3555-3559. PubMed ID: 29029165
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metabolic systems approaches update molecular insights of clinical phenotypes and cardiovascular risk in patients with homozygous familial hypercholesterolemia.
    Du Z; Li F; Jiang L; Li L; Du Y; Yu H; Luo Y; Wang Y; Sun H; Hu C; Li J; Yang Y; Jiao X; Wang L; Qin Y
    BMC Med; 2023 Jul; 21(1):275. PubMed ID: 37501168
    [TBL] [Abstract][Full Text] [Related]  

  • 13. How Can We Identify Very High-Risk Heterozygous Familial Hypercholesterolemia?
    Kataoka Y; Funabashi S; Doi T; Harada-Shiba M
    J Atheroscler Thromb; 2022 Jun; 29(6):795-807. PubMed ID: 35022364
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Familial hypercholesterolemia/autosomal dominant hypercholesterolemia: Molecular defects, the LDL-C continuum, and gradients of phenotypic severity.
    Foody JM; Vishwanath R
    J Clin Lipidol; 2016; 10(4):970-986. PubMed ID: 27578130
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Maternally inherited hypercholesterolemia does not modify the cardiovascular phenotype in familial hypercholesterolemia.
    Marco-Benedí V; Laclaustra M; Bea AM; Suarez-Tembra M; Plana N; Pinto X; Brea A; Sanchez-Hernandez RM; Civeira F
    Atherosclerosis; 2021 Mar; 320():47-52. PubMed ID: 33529866
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Elevated plasma PCSK9 level is equally detrimental for patients with nonfamilial hypercholesterolemia and heterozygous familial hypercholesterolemia, irrespective of low-density lipoprotein receptor defects.
    Lambert G; Petrides F; Chatelais M; Blom DJ; Choque B; Tabet F; Wong G; Rye KA; Hooper AJ; Burnett JR; Barter PJ; Marais AD
    J Am Coll Cardiol; 2014 Jun; 63(22):2365-73. PubMed ID: 24632287
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Familial hypercholesterolemia and estimation of US patients eligible for low-density lipoprotein apheresis after maximally tolerated lipid-lowering therapy.
    Vishwanath R; Hemphill LC
    J Clin Lipidol; 2014; 8(1):18-28. PubMed ID: 24528684
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Severe heterozygous familial hypercholesterolemia and risk for cardiovascular disease: a study of a cohort of 14,000 mutation carriers.
    Besseling J; Kindt I; Hof M; Kastelein JJ; Hutten BA; Hovingh GK
    Atherosclerosis; 2014 Mar; 233(1):219-23. PubMed ID: 24529147
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Value of Measuring Lipoprotein(a) During Cascade Testing for Familial Hypercholesterolemia.
    Ellis KL; Pérez de Isla L; Alonso R; Fuentes F; Watts GF; Mata P
    J Am Coll Cardiol; 2019 Mar; 73(9):1029-1039. PubMed ID: 30846097
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relation of Serum Lipoprotein(a) Levels to Lipoprotein and Apolipoprotein Profiles and Atherosclerotic Diseases in Japanese Patients with Heterozygous Familial Hypercholesterolemia: Familial Hypercholesterolemia Expert Forum (FAME) Study.
    Naito R; Daida H; Masuda D; Harada-Shiba M; Arai H; Bujo H; Ishibashi S; Koga N; Oikawa S; Yamashita S
    J Atheroscler Thromb; 2022 Aug; 29(8):1188-1200. PubMed ID: 34456199
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.